Emgality (Galcanezumab)

Emgality (galcanezumab-gnlm) is a calcitonin-gene-related peptide antagonist used in adult individuals for the:

• preventive treatment of migraine.
• treatment of episodic cluster headaches.

Recommended Dosage: 

Preventive Treatment of Migraine: The recommended dosage is 240 mg (two consecutive subcutaneous injections of 120 mg each) once as a loading dose, followed by monthly doses of 120 mg administered subcutaneously. If a dose is missed/skipped, administer as promptly as possible. Thereafter, medication can be scheduled monthly from the date of the final dose. 

Episodic Cluster Headache: The recommended dosage is 300 mg (3 consecutive subcutaneous injections of 100 mg each) at the onset of the cluster period, and then monthly until the end of the cluster period. If a dose is missed/skipped during a cluster period, administer it as soon as possible. Thereafter, dosage can be scheduled monthly from the date of the final dose until the end of the cluster period. 

• Critical hypersensitivity reactions including events of anaphylaxis, angioedema, and urticaria may occur. In case of a critically occurring hypersensitivity reaction, use of Emgality 120 mg/mL or 300 mg/mL should be discontinued promptly and relevant therapy started.
• There are limited findings from the use of Emgality in pregnant females. Animal findings do not represent direct or indirect critical effects in the context of reproductive toxicity. Human IgG is expected to pass the placental barrier. From a precautionary perspective, it is preferable to avoid the use of this medicine during pregnancy.
• It is not known whether Emgality is excreted in human milk. Human IgG is known to be excreted in human breast milk during the initial days after birth, which is reducing to low concentrations quickly afterward; consequently, a risk to breastfed infants should not be excluded. Afterward, the use of Emgality 300 mg/mL or 120 mg/mL could be considered during breast-feeding only in case clinically required.
• The effect of Emgality on human fertility has not been assessed. Fertility findings in animals do not represent hazardous effects with respect to men’s and women’s fertility.
• Galcanezumab injection may have a minimal influence on the potential to drive and operate any machinery. Vertigo may be established after the use of galcanezumab.

What documents are required to import EMGALITY to India?

EMGALITY (galcanezumab-gnlm) injection can be imported by patients or government hospitals on the name of the patients only. 

The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
  
• Patients diagnostic reports
  
• Patients ID proof (issued by the government of India)

The order will be confirmed only after the receipt of:

• A valid prescription from Doctor
  
• Import permit if applicable

EMGALITY (galcanezumab injection) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input

• On availability of Emgality in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
  
• Medicine Price.
  
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
  
• Ensuring 100% transparency.

IPN (Indian Pharma Network) can facilitate the supply of EMGALITY (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Emgality price in India. 

We take to guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

What is the Generic Name for the trade name drug Emgality®?

Galcanezumab-gnlm is a Generic Name for the trade name drug Emgality®.

What is the Manufacturer’s Name of Emgality®?

Emgality® is manufactured by Eli Lilly and Company.

Is Emgality® approved by the FDA?

Yes, Emgality® is approved by the FDA. Date of first or initial approval: 27th September 2018.

What is the dosage and form of Emgality® supplied?

Emgality® is supplied as 120 mg in a prefilled pen or syringe and 300 mg in three (100 mg) prefilled syringes for subcutaneous use. 

What are the most commonly reported side effects of Emgality®? 

The most commonly reported side effects of Emgality® treatment are injection site reactions.

How much does Emgality® cost in India?

The cost of Emgality in India can vary. In order to procure this CGRP antagonist legally, you can Call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

What are the storage conditions of Emgality®?

Store refrigerated at 2-8°C (36-46°F) in the original carton to protect the medicine from light until use. Avoid freezing and shaking.

Is it safe to buy Emgality® online in India?

Yes, one can buy Emgality online in India at the lowest price from the Indian Pharma Network (IPN) if the medicine Emgality® is not (yet) registered or is available in your country. We can help facilitate the supply of Emgality® through legal channels.